{"url_path":"/sec/hrmy/8-k/2026-07-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1802665/0001104659-26-084095-index.html","accession_number":"0001104659-26-084095","cik":"0001802665","ticker":"HRMY","issuer_name":"Harmony Biosciences Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1802665/0001104659-26-084095-index.html","primary_entity_key":"0001802665","primary_entity_name":"Harmony Biosciences Holdings, Inc."},"word_count":171,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n(d) Exhibits.\n\n​\n\n​\n\n​\n\nExhibit\n\n  ​ ​ ​\n\n​\n\nNo.\n\n​\n\nDescription\n\n​\n\n​\n\n​\n\n10.1\n\n​\n\n[Separation Agreement between Harmony Biosciences Management, Inc. and Glenn Reicin, dated July 16, 2026.](hrmy-20260716xex10d1.htm)\n\n​\n\n​\n\n​\n\n99.1\n\n​\n\n[Press release issued by the Company, dated July 16, 2026](hrmy-20260716xex99d1.htm).\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n**HARMONY BIOSCIENCES HOLDINGS, INC.**\n\n​\n\n​\n\nDate: July 16, 2026\n\nBy:\n\n/s/ Jeffrey M. Dayno, M.D.\n\n​\n\n​\n\nJeffrey M. Dayno, M.D.\n\n​\n\n​\n\nPresident and Chief Executive Officer\n\n​\n\n​\n\n​"}